References
- Biomarkers. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89–95.
- Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2019;34(10):1464–1470.
- Postuma RB, Berg D. Prodromal Parkinson’s disease: the decade past, the decade to come. Mov Disord. 2019 May;34(5):665–675.
- Helmich RC, Vaillancourt DE, Brooks DJ. The future of brain imaging in Parkinson’s disease. J Parkinsons Dis. 2018;8(s1):S47–S51.
- Lorio S, Sambataro F, Bertolino A, et al. The Combination of DAT-SPECT, structural and diffusion MRI predicts clinical progression in Parkinson’s disease. Front Aging Neurosci. 2019 Mar;11:57.
- Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018;17(7):618–628.
- Eusebi P, Giannandrea D, Biscetti D, et al. Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2017 Oct;32(10):1389–1400.
- Førland MG, Öhrfelt A, Dalen I, et al. Evolution of cerebrospinal fluid total α-synuclein in Parkinson’s disease. Parkinsonism Relat Disord. 2018;49:4–8.
- Abbasi N, Mohajer B, Abbasi S, et al. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson’s disease. Mov Disord. 2018;33:431–439.
- Bougea A, Stefanis L, Paraskevas GP, et al. Plasma alpha-synuclein levels in patients with Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci. 2019 May;40(5):929–938.
- Bougea A, Koros C, Stefanis L. Salivary alpha-synuclein as a biomarker for Parkinson’s disease: a systematic review. J Neural Transm (Vienna). 2019 Aug 10;126:1373–1382.
- Havelund JF, Heegaard NHH, Færgeman NJK, et al. Biomarker research in Parkinson’s disease using metabolite profiling. Metabolites. 2017 Aug 11;7(3):42.
- Chen CH, Lee BC, Lin CH. Integrated plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson’s disease. J Parkinsons Dis. 2020;10(1):77-88.
- Schneider SA, Boettner M, Alexoudi A, et al. Can we use peripheral tissue biopsies to diagnose Parkinson’s disease? A review of the literature. Eur J Neurol. 2016 Feb;23(2):247–261.
- Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone-based testing to generate exploratory outcome measuresin a phase 1 Parkinson’s disease clinical trial. Mov Disord. 2018;33:1287–1297.